Wave Life Sciences Touts Positive Update From Its Lead Huntington’s Program – WAVE Life Sciences (NASDAQ:WVE)
[ad_1] Wave Life Sciences Ltd WVE announced an update to the ongoing Phase 1b/2a SELECT-HD trial of WVE-003 for Huntington’s disease (HD). Eighteen (18) participants have been dosed in…
EXCLUSIVE: Newly Listed Virax Biolabs Launches Monkeypox Antigen Rapid Test – Virax Biolabs Group (NASDAQ:VRAX)
[ad_1] Virax Biolabs Group Ltd VRAX has announced the distribution of a Monkeypox Antigen Rapid Test Kit launched in the European markets accepting the CE mark. The specialized diagnostic kits can…
Judge Says Yes To $13B UnitedHealth-Change Healthcare Merger: Report – UnitedHealth Group (NYSE:UNH)
[ad_1] A U.S. judge on Monday denied the Justice Department’s request to stop UnitedHealth Group Inc’s UNH $13 billion buyout deal for Change Healthcare Inc CHNG. The Justice Department had filed a…
AstraZeneca’s Blood Clot Treatment Hits Primary Goal In Rare Blood Disorder Trial – AstraZeneca (NASDAQ:AZN), AstraZeneca (OTC:AZNCF)
[ad_1] AstraZeneca Plc AZN said its Danicopan add-on anti-blood-clotting drug met a primary endpoint in the ALPHA phase 3 trial in patients with paroxysmal nocturnal hemoglobinuria (PNH) who experience clinically significant extravascular…
Pfizer (NYSE:PFE) – Pfizer Starts Pivotal Phase 3 Study of mRNA-Based Influenza Vaccine
[ad_1] Pfizer Inc PFE has dosed the first participants in the Phase 3 trial of its quadrivalent modified RNA (modRNA) influenza vaccine candidate in approximately 25,000 healthy U.S. adults. Influenza annually…